Haleon plc (NYSE:HLN) Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp grew its position in Haleon plc (NYSE:HLN) by 13.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,509,400 shares of the company’s stock after acquiring an additional 418,609 shares during the quarter. Van ECK Associates Corp owned about 0.08% of Haleon worth $33,480,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Fortitude Family Office LLC acquired a new stake in shares of Haleon in the third quarter valued at approximately $28,000. Versant Capital Management Inc lifted its holdings in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Haleon during the fourth quarter worth $35,000. Finally, Spire Wealth Management acquired a new stake in shares of Haleon during the fourth quarter worth $39,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Price Performance

Haleon stock opened at $9.71 on Friday. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The business has a fifty day moving average of $9.54 and a two-hundred day moving average of $9.80. The company has a market cap of $43.93 billion, a P/E ratio of 28.54, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.